INFORMAZIONI SU QUESTO ARTICOLO

Cita

Figure 1

Workflow used to assess the metabolic profile of the blood-brain barrier model exposed to mycotoxins with and without pumpkin extract. BBB – blood brain barrier; LC-ESI-QTOF-MS – liquid chromatography-electrospray ionisation quantitative time of flight-mass spectrometry
Workflow used to assess the metabolic profile of the blood-brain barrier model exposed to mycotoxins with and without pumpkin extract. BBB – blood brain barrier; LC-ESI-QTOF-MS – liquid chromatography-electrospray ionisation quantitative time of flight-mass spectrometry

Figure 2

Venn diagrams of the number of significant metabolites (p<0.05) after 2-hour mycotoxin exposure (100 nmol/L per mycotoxin) without pumpkin extract (A) and with pumpkin extract (500 nmol/L) (B)
Venn diagrams of the number of significant metabolites (p<0.05) after 2-hour mycotoxin exposure (100 nmol/L per mycotoxin) without pumpkin extract (A) and with pumpkin extract (500 nmol/L) (B)

Log2FC values of metabolites with significantly changed quantity (p<0.05) compared to respective controls (control containing vehicle or vehicle + pumpkin extract) found in the basal media after 2-hour exposure to mycotoxins (100 nmol/L each) with or without pumpkin extract (500 nmol/L beta-carotene equivalent)

Compound BEA BEA+E OTA OTA+E ZEA ZEA+E OTA+ZEA OTA+ZEA+E BEA+OTA+ZEA BEA+OTA+ZEA+E
(2R,3S,7S,10S)-2,3,7,10-tetramethyl dodecahydrocyclo 15.57 penta[b]quinolizin-2-ol
(5E)-(3S)-1alpha,25-dihydroxy-3-deoxy-3-thiavitamin D3 3-oxide / (5E)-(3S)-1alpha,25-dihydroxy-3-deoxy-3-thiacholecalciferol 3-oxide 15.68
12-epi leukotriene B4-d4 18.12
12,13-DiHOME-d4 18.35 18.49 18.34
14,15-LTE4 15.56 15.56 15.56
2-(3-phenylpropyl)pyridine 20.60 19.28 17.84
2-butyl-5-methyl-4-propyloxazole 15.70 15.49 15.79 15.98 15.88
2-ethyl-5-methylpyridine 19.36
23--(propenal, 1,3-benzodioxol-5-yl)- -19.15 18.18 -19.15 16.59 17.06 1.96 -19.15 1.87
2glucinolcarboxylate -protocatechoylphloro -16.29 -16.29 -16.29
2,6-dihydroxy-4-methoxytoluene 2.06
3-methylfluoranthene 16.09
3-methylxanthine 16.28
3,4-dichlorophenol -17.93 -17.93 -17.93 -17.93
4-(3-hydroxy-7-phenyl-6-heptenyl)-1,2-benzenediol 17.37
6-hydroxy-4-decanolide 16.77 16.37
67--hydroxykaempferol rutinoside -16.32 17.04 17.18 -16.32
6'-hydroxy-2,3,4,5,2',3',4'-heptamethoxychalcone 17.06
9-docosene 16.35 16.94 16.63 16.65 16.58 16.33 16.38
Asp-Met-OH 16.18 16.80
(7R)-7,15,17-trihydroxy-11-methyl-octadeca-121-oxabicyclo[(14),15,17-trien- 12.4.0] 13-one -17.71 -17.71 -17.71 -17.71 -1.68
Dihydromorelloflavone -16.68 -16.18 -16.18 -16.18 -16.18
Dimethylmaleic anhydride acid 17.61 18.04 16.06 17.80 17.12 2.05 17.75 1.92
Dodemorph -16.98 18.23 -16.98 -16.82 -16.98 16.30 16.16
Herbacetin 8-(2'',3'',4''-triacetylxyloside) 15.76
Hexazinone -18.83 -16.76 -16.76 -18.83
Ketophenylbutazone 17.33 17.17
Mercaptoethanol 16.46 19.32 -19.14
Methylmethionine sulfonium 0.73
N-(ethyl) 2'-(4arachidonoyl -benzenesulfonamide)- amine 21.56 21.28 19.63 16.46 17.65 21.39
N-(2'-(4-benzenesulfonamide)-ethyl) arachidonoyl amine 17.29 17.69 18.54
Nigrifactin 18.22 18.52
Oleamide 16.96
Oleic acid(d2) 15.34
Peroxyoctanoic acid 1.53
PG(16:0/0:0) -17.39 -17.11 -17.39 -17.11 -17.11 -17.39 -17.11 -17.39 -17.11
Pregna-4,16-diene-3,11,20-trione 17.12
Propyl levulinate 17.22
Prostaglandin D2-1-glyceryl ester 17.60 18.09
Prostaglandin D2-1-glyceryl
ester
Rhamnetin 3-rhamnoside 16.60 17.31 16.07
Spiromesifen 16.13 16.45
Streptonigrin 16.70 16.51
Tioconazole 19.47
Vestitone 7-glucoside 17.07 17.05
Xestoaminol C -16.08 -16.70 -16.08 16.50 -16.72 -16.70
eISSN:
1848-6312
Lingue:
Inglese, Slovenian
Frequenza di pubblicazione:
4 volte all'anno
Argomenti della rivista:
Medicine, Basic Medical Science, other